1. Home
  2. IVVD

as of 11-19-2026 3:45pm EST

$0.46
$0.04
-8.90%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Founded: 2020 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 212.6M IPO Year: 2021
Target Price: $10.00 AVG Volume (30 days): 3.4M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.38 EPS Growth: 79.02
52 Week Low/High: $0.49 - $3.01 Next Earning Date: 11-16-2026
Revenue: $53,426,000 Revenue Growth: 110.47%
Revenue Growth (this year): 12.92% Revenue Growth (next year): 44.18%
P/E Ratio: -1.32 Index:
Free Cash Flow: -58290000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 16, 2026 · 100% conf.

AI Prediction BUY

1D

+8.78%

$0.58

Act: -3.71%

5D

+20.25%

$0.64

20D

+3.33%

$0.55

Price: $0.53 Prob +5D: 100% AUC: 1.000
0001193125-26-462025

EX-99.1

2 ivvd-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights

• DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communicated

• Updated data timing driven by dialogue between Invivyd and the U.S. FDA 1) to refine details on the Accelerated Approval approach for VYD2311, and 2) to expand the accelerated regulatory approach and enable rapid development of future Invivyd monoclonal antibodies, including Invivyd’s measles antibody candidate; further update to be provided with DECLARATION interim analysis data

• Achieved Q3 2026 PEMGARDA® (pemivibart) net product revenue of $15.4 million, representing 18% growth versus Q3 2025 net product revenue of $13.1 million

• Appointed Chairman Marc W. Elia as Chief Executive Officer

• Announced positive topline results from LIBERTY Phase 3 clinical trial, which demonstrated VYD2311 safety and tolerability superior to an mRNA-based COVID-19 vaccine and lack of interference with vaccine-induced neutralizing antibody titers

• Announced initiation of FLINTLOCK Phase 2 clinical trial of VYD2311, which will evaluate VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injury

• Investments being made in commercial preparedness for VYD2311; Invivyd plans to host a Medical and Commercial Investor Event in 1H 2027 to describe commercial plans and early expressions of institutional demand

• Q3 2026 ending cash and cash equivalents of $126.4 million

NEW HAVEN, Conn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.

“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury,” said Marc Elia, Chairman and Chief Executive Officer of Invivyd. “While our DECLARATION data readout timing has been updated as we continued to work with regulators and policymakers on immunization regulation in America broadly, we are pleased that U.S. regulators understand the important role monoclonal antibodies can play in infectious disease going forward. We look forward to providing DECLARATION data and a regulatory update imminently, and we appreciate investor patience as we endeavor to set the stage for anticipated rapid advancement should VYD2311 DECLARATION data demonstrate an attractive clinical profile.”

“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies,” commented Bill Duke, Chief Financial Officer of Invivyd. “With a bolus of REVOLUTION clinical program spend in the rear view at this time, we look forward to a new posture of increased operating efficiency while we work to bring VYD2311 to vulnerable Americans as fast as possible.”

Third Quarter 2026 and Recent Company Highlights

PEMGARDA® Commercial Performance & Regulatory Update

• PEMGARDA net product revenue was $15.4 million for the quarter ended September 30, 2026, compared to $13.1 million for the quarter ended September 30, 2025. Growth of 18% was driven primarily by increased patient demand.

• In July 2026, Invivyd announced receipt of twelve months’ advanced notice of emergency use authorization (EUA) termination for PEMGARDA and that the company is in dialogue with the U.S. Food and Drug Administration (FDA) about appropriate next steps.

Research & Development (R&D) Highlights

COVID-19

• Invivyd continued to advance its REVOLUTION program, which is Invivyd’s development program for VYD2311 that is designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans:

• LIBERTY: In June 2026, Invivyd announced first participants dosed and completion of enrollment in LIBERTY, a Phase 3 clinical trial to evaluate the safety and tolerability of VYD2311 antibody versus mRNA COVID vaccine and to characterize the safety and immunology of antibody and mRNA vaccine co-administration. In September 2026, Invivyd announced positive topline results from LIBERTY demonstrating VYD2311 safety and tolerability superior to an mRNA-based COVID-19 vaccine:

• VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine.

• VYD2311 combined with an mRNA-based COVID-19 vaccine demonstrated no interference with vaccine-induced neutralizing titers and ins

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 13, 2026 · 100% conf.

AI Prediction BUY

1D

+9.33%

$0.75

Act: +6.45%

5D

+16.72%

$0.80

20D

+0.85%

$0.69

Price: $0.69 Prob +5D: 100% AUC: 1.000
0001193125-26-349193

EX-99.1

2 ivvd-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

• Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million

• Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand

• DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion

• LIBERTY study fully dosed with top-line data anticipated in late Q3 2026

• Strong balance sheet with Q2 2026 ending cash and cash equivalents of $160.1 million anticipated to provide runway through DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311

NEW HAVEN, Conn., August 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.

“With our VYD2311 DECLARATION and LIBERTY clinical trials planned to wrap up in the coming weeks, we are looking forward to the next steps for vulnerable Americans,” said Marc Elia, Chairman of the Board of Invivyd. “The public health need for antibody-based protection with attractive safety is enormous, and we are confident that many public health leaders and policy makers in the United States understand the importance of having non-vaccine options available for the American public health.”

“We are pleased with continued growth of PEMGARDA, especially in the face of understandably diminished COVID vaccine utilization,” commented Bill Duke, Chief Financial Officer of Invivyd. “We are pleased with our strong cash position as we approach planned top-line data for our VYD2311 pivotal program later this quarter. We have continued to diligently manage expenses, albeit during a period of critical heavy clinical investment in our pivotal VYD2311 program, which we expect to complete shortly as we move toward potential launch of VYD2311, if approved.”

Second Quarter 2026 and Recent Company Highlights

PEMGARDA® Commercial Performance & Regulatory Update

• PEMGARDA net product revenue was $14.3 million for the quarter ended June 30, 2026, compared to $11.8 million in for the quarter ended June 30, 2025. Growth of 21% was driven by increased patient demand.

• In July 2026, Invivyd announced receipt of twelve months’ advanced notice of emergency use authorization (EUA) termination for PEMGARDA and that the company is in dialogue with the U.S. Food and Drug Administration (FDA) about appropriate next steps.

Research & Development (R&D) Highlights

COVID-19

• Invivyd continued to advance its REVOLUTION program, which is Invivyd’s development program for VYD2311 that is designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans:

• DECLARATION: Following trial initiation in late 2025, the DECLARATION pivotal clinical trial recruitment progressed rapidly with full initial enrollment achieved in March 2026. In April 2026, Invivyd announced it had conducted a prospectively designed, conservative, algorithmic sample size re-estimation pooled, blinded analysis for the DECLARATION clinical trial aimed at supporting adequate COVID-19 clinical events and associated statistical power given the variability of COVID-19 attack rates, and, in June 2026, Invivyd announced completion of enrollment in the upsized DECLARATION clinical trial. DECLARATION is designed to support potential Biologics License Application (BLA) submission, with top-line data planned later in Q3 2026.

• LIBERTY: In June 2026, Invivyd announced first participants dosed and completion of enrollment in LIBERTY, a Phase 3 clinical trial to evaluate the safety and tolerability of VYD2311 antibody versus mRNA COVID vaccine and to characterize the safety and immunology of antibody and mRNA vaccine co-administration. The LIBERTY study is now fully dosed, with top-line data anticipated in late Q3 2026.

• DRUMMER: Invivyd agreed with the FDA on an initial pediatric study plan to support potential BLA submission for VYD2311 in children aged 0-11 years; the DRUMMER pediatric clinical trial will be actioned only if the pivotal DECLARATION clinical trial is successful.

• Long COVID: In January 2026, Invivyd and the SPEAR (Spike Protein Elimination and Recovery) Study Group announced the plan to initiate a Phase 2 clinical trial evaluating VYD2311 in individuals with Long COVID or COVID vaccine injury. The Phase 2 clinical trial is expected to be initiated mid-2026.

Measles

• In April 2026, Invivyd announced advancement of a measles monoclonal antibody candidate, VMS063. VMS063 is a novel, highly potent, broadly in vitro neutralizing

2026
Q1

Q1 2026 Earnings

8-K SELL

May 14, 2026 · 100% conf.

AI Prediction SELL

1D

-2.20%

$1.13

Act: +3.88%

5D

-14.98%

$0.99

Act: -4.31%

20D

-4.18%

$1.11

Act: -33.62%

Price: $1.16 Prob +5D: 0% AUC: 1.000
0001193125-26-222762

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784726355.7f52f07

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: